Tris Pharma Inc. can’t be sued by the state of Texas for manipulating test results on medication to treat minors for ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced that the company ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. The company tested cebranopadol, a dual nociceptin ...

Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up a submission for approval to the US Food and Drug Administration (FDA).

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that ...

MONMOUTH JUNCTION, N.J., Oct. 19, 2022 /PRNewswire/ -- Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that ...

Tris Pharma has received additional ex-US approvals for its attention deficit hyperactivity disorder (ADHD) treatments, ...

Tris Pharma Inc., the New Jersey manufacturer of infant ibuprofen, on Thursday expanded the voluntary recall of the product that it began in early December, citing the small chance of elevated ...

Chronic low back pain (CLBP) is a widespread and long-lasting condition defined by lower back pain that lasts for at least 12 ...

MONMOUTH JUNCTION, N.J., July 27, 2022 /PRNewswire/ -- Tris Pharma, Inc. ('Tris'), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that it has ...